EHA Library - The official digital education library of European Hematology Association (EHA)

CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES WITH TRANSFORMATION TO ACUTE LYMPHOBLASTIC LEUKAEMIA
Author(s): ,
Filipe Martins
Affiliations:
Haematology,Centre Hospitalier Universitaire Vaudois,Lausanne,Switzerland
,
Jacqueline Pouw-Schoumans
Affiliations:
Cytogenetics,Centre Hospitalier Universitaire Vaudois,Lausanne,Switzerland
,
Razvan Georg Racila
Affiliations:
Haematology,University clinics Freiburg,Freiburg,Germany
,
Olivier Spertini
Affiliations:
Haematology,Centre Hospitalier Universitaire Vaudois,Lausanne,Switzerland
Sabine Blum
Affiliations:
Haematology,Centre Hospitalier Universitaire Vaudois,Lausanne,Switzerland
(Abstract release date: 05/18/17) EHA Library. Blum S. 05/18/17; 182638; PB1924
Dr. Sabine Blum
Dr. Sabine Blum
Contributions
Abstract

Abstract: PB1924

Type: Publication Only

Background
Myelodysplastic syndromes are heterogeneous diseases with variable probability of developing a transformation to acute leukaemia. The vast majority of these cases present a transformation to acute myeloid leukaemia. We here describe a series of 4 cases of MDS/CMML with evolution to acute lymphoblastic leukaemia. These events are very rare and are to date only published as single cases.

Aims
The aim of these study is to better define cases of MDS transforming to ALL.

Methods
We describe 4 cases of patients suffering from MDS who in the course of their disease presented with ALL. Three of these cases presented in 1 centre, 1 in the other, all cases were documented in a 17-year time span.

We than performed a literature research including at the moment 37 cases of MDS transforming to ALL described as case reports.

Results
Subtypes of MDS are varying from low risk MDS with deletion (5q) (del(5q)) to refractory anaemia with excess of blasts in transformation (RAEB-T), classified as AML in newer WHO classifications (2008 and 2016) and CMML, classified as MDS/MPS nowadays. Even if MDS subgroups are manifold, cytogenetic results are less so. Two of the 4 patients described demonstrated KMT2A rearrangements, 1 already at MDS presentation, the other at ALL presentation. One patient presented with del(5q).

Of the 37 cases we identified in the literature, 7 presented with del(5q) and 2 showed with anomalies of the 11q23 locus.

Conclusion
KMT2A is known to be a gene involved in myeloid neoplasms as well as in acute lymphoblastic leukaemia. In a small series of cases like this one, it is not excluded that ALL following MDS is only by chance and “bad luck”, but at least in the patient showing the same translocation at MDS presentation and at ALL presentation, both diseases seem to be related. MLL as a cytogenetic event enabling the disease a switch from one phenotype (myeloid) to the other (lymphoblastic) could be a possible explanation for this phenomenon. KMT2A rearrangement in MDS is an extremely rare event, but could explain part of these rare changelings of MDS transforming to ALL.

Further studies are needed to confirm this hypothesis, and molecular examination is needed to characterise the event enabling a myeloid phenotype to switch to a lymphoblastic one.
The reason why del(5q) seems to be present in a high proportion of MDS patients transforming to ALL is not clear, further studies need to be performed.

Session topic: 10. Myelodysplastic syndromes - Clinical

Keyword(s): MDS, ALL, 11q23

Abstract: PB1924

Type: Publication Only

Background
Myelodysplastic syndromes are heterogeneous diseases with variable probability of developing a transformation to acute leukaemia. The vast majority of these cases present a transformation to acute myeloid leukaemia. We here describe a series of 4 cases of MDS/CMML with evolution to acute lymphoblastic leukaemia. These events are very rare and are to date only published as single cases.

Aims
The aim of these study is to better define cases of MDS transforming to ALL.

Methods
We describe 4 cases of patients suffering from MDS who in the course of their disease presented with ALL. Three of these cases presented in 1 centre, 1 in the other, all cases were documented in a 17-year time span.

We than performed a literature research including at the moment 37 cases of MDS transforming to ALL described as case reports.

Results
Subtypes of MDS are varying from low risk MDS with deletion (5q) (del(5q)) to refractory anaemia with excess of blasts in transformation (RAEB-T), classified as AML in newer WHO classifications (2008 and 2016) and CMML, classified as MDS/MPS nowadays. Even if MDS subgroups are manifold, cytogenetic results are less so. Two of the 4 patients described demonstrated KMT2A rearrangements, 1 already at MDS presentation, the other at ALL presentation. One patient presented with del(5q).

Of the 37 cases we identified in the literature, 7 presented with del(5q) and 2 showed with anomalies of the 11q23 locus.

Conclusion
KMT2A is known to be a gene involved in myeloid neoplasms as well as in acute lymphoblastic leukaemia. In a small series of cases like this one, it is not excluded that ALL following MDS is only by chance and “bad luck”, but at least in the patient showing the same translocation at MDS presentation and at ALL presentation, both diseases seem to be related. MLL as a cytogenetic event enabling the disease a switch from one phenotype (myeloid) to the other (lymphoblastic) could be a possible explanation for this phenomenon. KMT2A rearrangement in MDS is an extremely rare event, but could explain part of these rare changelings of MDS transforming to ALL.

Further studies are needed to confirm this hypothesis, and molecular examination is needed to characterise the event enabling a myeloid phenotype to switch to a lymphoblastic one.
The reason why del(5q) seems to be present in a high proportion of MDS patients transforming to ALL is not clear, further studies need to be performed.

Session topic: 10. Myelodysplastic syndromes - Clinical

Keyword(s): MDS, ALL, 11q23

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies